Athenex Inc (ATNX) Stake Boosted by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC grew its position in shares of Athenex Inc (NASDAQ:ATNX) by 80.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,004 shares of the company’s stock after acquiring an additional 28,178 shares during the period. Essex Investment Management Co. LLC’s holdings in Athenex were worth $979,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Barclays PLC raised its stake in shares of Athenex by 426.5% during the first quarter. Barclays PLC now owns 5,913 shares of the company’s stock valued at $100,000 after acquiring an additional 4,790 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Athenex by 363.2% during the second quarter. Legal & General Group Plc now owns 6,930 shares of the company’s stock valued at $129,000 after acquiring an additional 5,434 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Athenex during the first quarter valued at about $208,000. Metropolitan Life Insurance Co. NY bought a new position in Athenex in the second quarter worth about $266,000. Finally, A.R.T. Advisors LLC bought a new position in Athenex in the first quarter worth about $289,000. 19.83% of the stock is owned by hedge funds and other institutional investors.

In other Athenex news, Director Jinn Wu bought 12,500 shares of the firm’s stock in a transaction on Monday, October 15th. The stock was acquired at an average price of $13.47 per share, with a total value of $168,375.00. Following the completion of the purchase, the director now owns 311,208 shares of the company’s stock, valued at $4,191,971.76. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Song-Yi Zhang sold 102,734 shares of the firm’s stock in a transaction that occurred on Wednesday, August 22nd. The shares were sold at an average price of $17.24, for a total transaction of $1,771,134.16. Following the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $68,960. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 27,000 shares of company stock valued at $405,120 and have sold 344,317 shares valued at $5,859,972. 29.50% of the stock is currently owned by company insiders.

A number of equities analysts recently issued reports on ATNX shares. ValuEngine downgraded shares of Athenex from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th. BidaskClub downgraded shares of Athenex from a “buy” rating to a “hold” rating in a research note on Thursday, June 28th. Finally, Zacks Investment Research downgraded shares of Athenex from a “hold” rating to a “sell” rating in a research note on Friday, August 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $22.75.

ATNX stock opened at $13.52 on Friday. Athenex Inc has a 1 year low of $13.15 and a 1 year high of $20.90.

Athenex (NASDAQ:ATNX) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.10). Athenex had a negative return on equity of 73.37% and a negative net margin of 122.29%. The company had revenue of $11.57 million during the quarter. As a group, research analysts forecast that Athenex Inc will post -2 EPS for the current fiscal year.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Featured Story: The risks of owning bonds

Want to see what other hedge funds are holding ATNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athenex Inc (NASDAQ:ATNX).

Institutional Ownership by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply